Mereo Downgraded by JP Morgan on Setrusumab Risk JP Morgan downgraded Mereo to Neutral on Mar 23, 2026 citing setrusumab regulatory uncertainty; EMA reviews average 210 days and FDA reviews ~6–10 months (Seeking Alpha; EMA; FDA).

Mereo Downgraded by JP Morgan on Setrusumab Risk: JP Morgan downgraded Mereo to Neutral on Mar 23, 2026 citing setrusumab regulatory uncertainty; EMA reviews average 210 days and FDA reviews ~6–10 months (Seeking Alpha; EMA; FDA). 👈 Read full analysis #Mereo #JPMorgan #Setrusumab #FDA #EMA

Ultragenyx Pharmaceutical Faces Securities Class Action Over Efficacy Claims Regarding Setrusumab A securities class action has been filed against Ultragenyx Pharmaceutical, alleging misleading efficacy claims about Setrusumab. Investors are encouraged to seek legal counsel.

Ultragenyx Pharmaceutical Faces Securities Class Action Over Efficacy Claims Regarding Setrusumab #United_States #New_York #Class_Action #Ultragenyx #setrusumab

Ultragenyx Sees Stock Drop After Phase III Study Results Fail to Meet Expectations Ultragenyx Pharmaceutical's stock price declines following the disappointing results from its Phase III Orbit and Cosmic studies, prompting investor concern.

Ultragenyx Sees Stock Drop After Phase III Study Results Fail to Meet Expectations #USA #New_York #IPO #Ultragenyx #setrusumab